Cardiovascular Drug Could Deliver Esophageal Cancer Treatments
Phase II study results from French biotech Cerenis Therapeutics show that a drug initially developed…
26/06/2018 - 2 minutes
Cerenis
ADVERTISEMENT
Do you want to remove this advert? Become a member!
Grab the Tissues: Here are the 8 Biggest European Biotech Clinical Failures of 2017
As 2016 was a tough year for biotech, 2017 was under pressure to turn things…
12/12/2017 - 7 minutes
French Biotech fails Second Phase II Trial for Cardiovascular Disease
Cerenis therapeutic's lead candidate CER-001 has failed Phase II for the treatment of patients with…
20/03/2017 - 3 minutes
EMA give Orphan Drug Designation to the CER-001 of Cerenis
Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for…
03/09/2014 - 3 minutes
